Summary

Australia Lung Cancer Diagnostics Market Size and Forecast 2026-2034
Australia Lung Cancer Diagnostics Market will grow from US$ 381.26 Million in 2025 to US$ 738.34 Million in 2034, at a Compound Annual Growth Rate (CAGR) of 7.62% from 2026–2034. The market is driven by the increasing incidence of lung cancer, growing adoption of early screening programs, and advancements in diagnostic technologies such as low-dose computed tomography (LDCT), molecular diagnostics, and liquid biopsy. Rising healthcare expenditure, supportive government initiatives, and the expanding use of precision medicine are further expected to fuel market growth throughout the forecast period.

Australia Lung Cancer Diagnostics Industry Overview
Lung cancer diagnostics refers to the range of tests and procedures used to detect, confirm, and classify lung cancer at an early stage. These diagnostics include imaging techniques such as chest X-rays, computed tomography (CT) scans, positron emission tomography (PET) scans, bronchoscopy, biopsy procedures, molecular testing, and liquid biopsy. The primary purpose of lung cancer diagnostics is to identify cancerous cells, determine the stage of the disease, and guide personalized treatment decisions.
In Australia, lung cancer diagnostics have gained significant popularity due to the rising incidence of lung cancer and increasing awareness about the benefits of early detection. Government-supported screening initiatives, advancements in diagnostic technologies, and growing adoption of precision medicine are encouraging greater use of molecular and genetic testing. The widespread availability of advanced healthcare facilities and increasing investments in cancer research are further supporting market growth. As a result, lung cancer diagnostics play a crucial role in improving patient outcomes, survival rates, and overall cancer management across Australia.

Estimated cancer incidence in Australia, 2025
Cancer Type Cases
Prostate cancer 28,868
Breast cancer 20,336
Melanoma of the skin 17,443
Lung cancer 15,108
Colorectal cancer 14,784
Non-Hodgkin lymphoma 6,920
Kidney cancer 4,868
Pancreatic cancer 4,825
Thyroid cancer 4,355
Uterine cancer 3,493
Source: Cancer Australia

Lung Cancer Diagnostic product launches specifically in Australia
Date Product/Technology Company/Organization Description
Jan-23 Lung Cancer Liquid Biopsy Test BioMark Diagnostics Advanced blood-based liquid biopsy platform progressed toward commercialization for early lung cancer detection.
2023 Comprehensive Genomic Profiling Expansion Multiple Australian Cancer Centers Increased adoption of NGS-based genomic profiling for NSCLC diagnosis and treatment selection.
2023 AI-Powered Lung Nodule Assessment Platform Optellum Expansion of AI-assisted lung cancer risk assessment technology for earlier diagnosis.
2024 Spectroscopic Liquid Biopsy Platform Dxcover Advancement of blood-based cancer detection technology including lung cancer applications.
2024 ctDNA Liquid Biopsy Testing Expansion Australian Oncology Networks Broader use of circulating tumor DNA (ctDNA) testing for NSCLC molecular profiling.
Feb-25 National Lung Cancer Screening Program Preparations Australian Healthcare System Expansion of LDCT-based screening infrastructure ahead of nationwide implementation.
2025 Comprehensive Genomic Profiling Programs Australian Cancer Centers Increased integration of molecular diagnostics into routine lung cancer care pathways.
Jun-25 Shield Multi-Cancer Detection Test Guardant Health Received FDA Breakthrough Device Designation, strengthening global adoption of liquid biopsy technologies relevant to lung cancer diagnostics.
Oct-25 Advanced Liquid Biopsy Applications Australian Thoracic Oncology Group Growing clinical implementation of liquid biopsy for lung cancer diagnosis and monitoring.
2025 AI-Enhanced Imaging Diagnostics Multiple Australian Hospitals Expansion of AI-supported CT scan interpretation and lung nodule assessment platforms.

Growth Driver in the Australian Lung Cancer Diagnostics Market
Rising Incidence of Lung Cancer
The increasing prevalence of lung cancer across Australia is a major factor driving demand for advanced diagnostic solutions. While smoking remains a significant risk factor, a growing number of cases are being identified among non-smokers, elderly individuals, and people exposed to environmental pollutants, occupational hazards, and genetic risk factors. Australia’s aging population is particularly contributing to the rising disease burden, as the likelihood of developing lung cancer increases with age. This trend has highlighted the critical importance of timely and accurate diagnosis to improve treatment outcomes and survival rates. Healthcare providers are increasingly adopting advanced diagnostic techniques that enable early-stage detection, when treatment is most effective. In response, healthcare organizations and research institutions are investing heavily in innovative screening and diagnostic technologies. The growing need to identify lung cancer at earlier stages is encouraging the expansion of diagnostic services throughout the country, making the rising incidence of the disease one of the strongest growth drivers for the
Australia Lung Cancer Diagnostics Market.
Advancements in Diagnostic Technologies
Technological innovation is transforming the landscape of lung cancer diagnostics in Australia and significantly contributing to market growth. Modern diagnostic approaches such as liquid biopsy allow clinicians to detect cancer-related biomarkers through simple blood tests, reducing the need for invasive tissue sampling procedures. Artificial intelligence-powered imaging systems are also improving the accuracy and speed of image interpretation, helping radiologists identify abnormalities with greater precision. In addition, next-generation sequencing (NGS) enables comprehensive genetic analysis of tumors, supporting personalized treatment strategies tailored to individual patients. These advancements are enhancing diagnostic efficiency while minimizing patient discomfort and procedural risks. The integration of digital health technologies and precision medicine into clinical practice is further improving the quality of cancer care. As healthcare providers continue to embrace innovative diagnostic tools, patients benefit from earlier detection, more accurate diagnoses, and better treatment planning. Consequently, ongoing technological progress remains a key catalyst for the expansion of the Australia Lung Cancer Diagnostics Market.

Growing Awareness and Screening Campaigns
Increasing awareness of lung cancer and the importance of early diagnosis is playing a crucial role in driving the adoption of diagnostic services across Australia. Government agencies, healthcare organizations, and non-profit groups are actively conducting public education campaigns to improve understanding of lung cancer symptoms, risk factors, and available screening options. These initiatives encourage individuals, particularly those in high-risk groups, to seek medical evaluations and participate in screening programs before symptoms become severe. Public health campaigns are also helping to reduce misconceptions about lung cancer and emphasize the benefits of early intervention. Furthermore, outreach efforts targeting rural and underserved communities are improving access to information and healthcare services. As awareness continues to grow, more Australians are undergoing routine screenings and diagnostic assessments, leading to earlier detection and improved treatment outcomes. The increasing participation in screening programs is expected to strengthen demand for advanced diagnostic technologies and support sustained growth in the Australia Lung Cancer Diagnostics Market.

Challenges in the Australia Lung Cancer Diagnostics Market
High Cost of Advanced Diagnostics
One of the primary challenges affecting the Australia Lung Cancer Diagnostics Market is the substantial cost associated with advanced diagnostic technologies. Innovative diagnostic methods such as next-generation sequencing (NGS), molecular testing, and liquid biopsies provide highly accurate and minimally invasive options for detecting lung cancer. However, these technologies often involve significant expenses related to equipment, laboratory infrastructure, and specialized expertise. As a result, many patients may face financial barriers, particularly if their healthcare coverage does not fully reimburse these procedures. The high costs also place pressure on healthcare providers and hospitals, which may be hesitant to invest in expensive technologies due to budget constraints. Consequently, access to cutting-edge diagnostic services remains uneven across different patient groups. This affordability challenge can delay diagnosis and limit the widespread adoption of innovative testing methods. Addressing cost-related barriers will be essential to ensuring broader access to advanced diagnostics and supporting the long-term development of the market.

Limited Access in Rural and Remote Areas
Ensuring equal access to lung cancer diagnostic services remains a significant challenge in Australia due to the country’s vast geographical landscape. Many rural and remote communities have limited access to specialized healthcare facilities, advanced imaging centers, pathology laboratories, and oncology services. In addition, shortages of trained healthcare professionals in these regions further restrict the availability of timely diagnostic care. Patients living outside major metropolitan areas often need to travel long distances to access screening, testing, and specialist consultations, resulting in delays in diagnosis and treatment initiation. Such delays can negatively affect patient outcomes, particularly for aggressive cancers like lung cancer where early detection is critical. Although telehealth services, mobile healthcare units, and government initiatives have improved access in some regions, disparities continue to exist. Overcoming these geographical and infrastructure-related challenges is essential to ensuring that all Australians receive timely, high-quality diagnostic services regardless of their location.

Australia Lung Cancer Diagnostics Imaging Test Market
The Australia Lung Cancer Diagnostics Imaging Test Market is experiencing steady growth due to the increasing use of advanced imaging technologies for early and accurate cancer detection. Imaging tests such as chest X-rays, computed tomography (CT) scans, low-dose CT (LDCT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans play a vital role in identifying lung abnormalities and determining disease progression. Among these, LDCT has gained significant attention because of its ability to detect lung cancer at an early stage, improving treatment outcomes and survival rates. Growing awareness regarding preventive healthcare and routine cancer screening is encouraging more individuals, particularly high-risk populations, to undergo imaging examinations. Technological advancements have enhanced image quality, reduced scanning times, and improved diagnostic precision, making imaging tests more reliable and accessible. Additionally, the integration of artificial intelligence into radiology workflows is helping clinicians detect suspicious lesions more effectively. These factors collectively support the expansion of the Australia Lung Cancer Diagnostics Imaging Test Market.

Australia Lung Cancer Diagnostics Biopsy Market
The Australia Lung Cancer Diagnostics Biopsy Market is growing as healthcare providers increasingly rely on biopsy procedures to confirm lung cancer diagnoses and guide treatment decisions. Biopsies remain the gold standard for identifying cancerous cells and determining tumor characteristics. Various biopsy techniques, including needle biopsy, bronchoscopy-guided biopsy, endobronchial ultrasound-guided biopsy, and surgical biopsy, are widely used depending on the patient’s condition and tumor location. The growing adoption of personalized medicine has further increased the importance of biopsy procedures because tissue samples are essential for molecular and genetic testing. Advances in minimally invasive biopsy techniques have reduced patient discomfort, shortened recovery times, and improved diagnostic accuracy. Furthermore, the rising incidence of lung cancer and the increasing demand for targeted therapies are creating a greater need for comprehensive tumor profiling. Hospitals and diagnostic centers across Australia are investing in advanced biopsy technologies to enhance patient outcomes, making biopsy-based diagnostics a critical segment within the country’s lung cancer diagnostics market.

Australia Small Cell Lung Cancer Diagnostics Market
The Australia Small Cell Lung Cancer Diagnostics Market is expanding as healthcare providers place greater emphasis on the early detection and management of aggressive lung cancer forms. Small cell lung cancer (SCLC) is characterized by rapid growth and early metastasis, making timely diagnosis essential for improving patient survival. Diagnostic approaches for SCLC typically include imaging tests, biopsy procedures, pathology analysis, and molecular testing. Increased awareness among healthcare professionals regarding the importance of prompt diagnosis is encouraging the adoption of advanced diagnostic solutions. Technological innovations in imaging and laboratory testing have improved the ability to detect small cell lung cancer at earlier stages, enabling quicker treatment initiation. In addition, ongoing research into biomarkers and molecular characteristics of SCLC is supporting the development of more precise diagnostic tools. The rising burden of lung cancer, combined with efforts to improve screening and diagnostic capabilities, is contributing to the growth of the Australia Small Cell Lung Cancer Diagnostics Market and enhancing the quality of cancer care nationwide.

Australia Lung Cancer Diagnostics Hospital Associated Labs Market
The Australia Lung Cancer Diagnostics Hospital Associated Labs Market is witnessing significant growth due to the increasing role of hospital-based laboratories in comprehensive cancer diagnosis. These laboratories provide a wide range of diagnostic services, including pathology testing, biomarker analysis, genetic profiling, molecular diagnostics, and tissue examination. Hospital-associated labs offer integrated diagnostic solutions that support clinicians in making accurate and timely treatment decisions. The growing adoption of precision medicine has increased demand for advanced laboratory testing, particularly for identifying genetic mutations and biomarkers linked to lung cancer. Investments in modern laboratory infrastructure, automation technologies, and digital pathology systems are improving testing efficiency and accuracy across Australian healthcare facilities. In addition, hospital laboratories benefit from close collaboration with oncology departments, enabling faster diagnosis and streamlined patient management. As the number of lung cancer cases continues to rise, hospital-associated laboratories are expected to play an increasingly important role in supporting early detection, personalized treatment planning, and overall improvements in patient outcomes.

New South Wales Lung Cancer Diagnostics Market
New South Wales represents one of the largest markets for lung cancer diagnostics in Australia due to its extensive healthcare infrastructure, large population base, and widespread access to advanced medical services. The state is home to numerous tertiary hospitals, cancer treatment centers, diagnostic laboratories, and research institutions that support comprehensive lung cancer detection and management. Increasing awareness regarding early cancer diagnosis has encouraged greater participation in screening and preventive healthcare programs. The adoption of advanced technologies such as low-dose computed tomography (LDCT), molecular diagnostics, liquid biopsy, and artificial intelligence-assisted imaging is improving diagnostic accuracy and reducing the time required for diagnosis. Additionally, New South Wales continues to invest in precision medicine initiatives that rely heavily on advanced diagnostic testing and biomarker analysis. The presence of highly skilled healthcare professionals and strong collaboration between hospitals and research organizations further supports market growth. As demand for personalized cancer care increases, the New South Wales Lung Cancer Diagnostics Market is expected to remain a key contributor to Australia’s overall diagnostics industry.

Victoria Lung Cancer Diagnostics Market
Victoria is a significant contributor to the Australian lung cancer diagnostics market, supported by its advanced healthcare system, strong medical research ecosystem, and increasing adoption of innovative diagnostic technologies. The state has established itself as a center for cancer research and clinical innovation, enabling the rapid integration of new diagnostic approaches into routine clinical practice. Hospitals and diagnostic centers are increasingly utilizing advanced imaging techniques, genetic testing, biomarker analysis, and next-generation sequencing to improve the detection and classification of lung cancer. The growing emphasis on precision medicine is encouraging healthcare providers to perform comprehensive molecular profiling, allowing treatments to be tailored according to individual patient characteristics. Furthermore, public awareness campaigns and healthcare initiatives have contributed to higher rates of early diagnosis and screening participation. Continuous investment in healthcare infrastructure and laboratory modernization is further enhancing diagnostic capabilities. These factors collectively support sustained growth in the Victoria Lung Cancer Diagnostics Market while improving patient outcomes and treatment effectiveness.

Queensland Lung Cancer Diagnostics Market
The Queensland Lung Cancer Diagnostics Market is witnessing steady growth due to increasing demand for early cancer detection services and ongoing expansion of healthcare infrastructure throughout the state. Queensland’s large and geographically diverse population has created a strong need for accessible diagnostic services across both metropolitan and regional communities. Healthcare providers are increasingly adopting advanced imaging technologies, pathology services, and molecular diagnostic tests to improve the accuracy and efficiency of lung cancer detection. Government initiatives aimed at strengthening regional healthcare services are helping reduce disparities in access to cancer diagnostics. In addition, telehealth platforms and digital healthcare solutions are improving communication between specialists and patients in remote locations. Rising awareness regarding the benefits of early diagnosis is encouraging more individuals to seek screening and diagnostic evaluations. As healthcare facilities continue to invest in modern equipment and specialized cancer care programs, Queensland is expected to experience sustained growth in lung cancer diagnostic services, supporting improved clinical outcomes and patient care across the state.

Western Australia Lung Cancer Diagnostics Market
Western Australia is emerging as an important market for lung cancer diagnostics due to increasing healthcare investments and growing efforts to improve access to specialized cancer care. The state’s vast geographical area presents unique challenges for healthcare delivery, making the expansion of diagnostic services a key priority. Hospitals and healthcare providers are investing in advanced imaging systems, molecular testing platforms, and laboratory technologies to enhance diagnostic accuracy and reduce delays in cancer detection. The adoption of minimally invasive diagnostic techniques and precision medicine approaches is further supporting market development. Additionally, initiatives aimed at improving healthcare accessibility in remote and rural communities are encouraging broader utilization of diagnostic services. Mobile health programs, telemedicine solutions, and regional healthcare partnerships are helping bridge the gap between urban and non-urban populations. Rising awareness of lung cancer risk factors and the importance of early detection is also contributing to increased demand for diagnostic testing. These developments position Western Australia as a growing and strategically important segment of the national lung cancer diagnostics market.

Market Segmentations
Diagnosis Test Type
- Imaging Test
- Biopsy
- Sputum Cytology
- Molecular Test
- Others

Cancer Type
- Non- Small Cell Lung Cancer
- Small Cell Lung Cancer

End-User
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others

States
- New South Wales
- Victoria
- Queensland
- Western Australia
- South Australia
- Australian Capital Territory
- Tasmania
- Northern Territory

All the Key players have been covered with 5 Viewpoints
- Overviews
- Key Person
- Recent Developments
- SWOT Analysis
- Revenue Analysis

Key Players Analysis
- Llumina
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- QIAGEN N.V.
- Roche Holding AG.
- Sanofi S.A.
- Agilent Technologies
- bioMérieux

ページTOPに戻る

Table of Contents

1. Introduction

2. Research & Methodology
2.1 Data Source
2.1.1 Primary Sources
2.1.2 Secondary Sources

2.2 Research Approach
2.2.1 Top-Down Approach
2.2.2 Bottom-Up Approach

2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. Australia lung Cancer Diagnostics Market
5.1 Historical Market Trends
5.2 Market Forecast

6. Market Share Analysis
6.1 By Diagnosis Test Type
6.2 By Cancer Type
6.3 By End User
6.4 By States

7. Diagnosis Test Type - Historical and Current Market Trends & Forecast
7.1 Imaging Test
7.2 Biopsy
7.3 Sputum Cytology
7.4 Molecular Test
7.5 Others

8. Cancer Type - Historical and Current Market Trends & Forecast
8.1 Non- Small Cell Lung Cancer
8.2 Small Cell Lung Cancer

9. End-User - Historical and Current Market Trends & Forecast
9.1 Hospital Associated Labs
9.2 Independent Diagnostic Laboratories
9.3 Diagnostic Imaging Centers
9.4 Cancer Research Institutes
9.5 Others

10. States - Historical and Current Market Trends & Forecast
10.1 New South Wales
10.2 Victoria
10.3 Queensland
10.4 Western Australia
10.5 South Australia
10.6 Australian Capital Territory
10.7 Tasmania
10.8 Northern Territory

11. Porter’s Five Forces Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes

12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat

13. Merger and Acquisition

14. Key Players Analysis
14.1 Llumina
14.1.1 Overviews
14.1.2 Key Person
14.1.3 Recent Developments
14.1.4 SWOT Analysis
14.1.5 Revenue Analysis

14.2 Abbott Laboratories
14.2.1 Overviews
14.2.2 Key Person
14.2.3 Recent Developments
14.2.4 SWOT Analysis
14.2.5 Revenue Analysis

14.3 Thermo Fisher Scientific, Inc.
14.3.1 Overviews
14.3.2 Key Person
14.3.3 Recent Developments
14.3.4 SWOT Analysis
14.3.5 Revenue Analysis

14.4 QIAGEN N.V.
14.4.1 Overviews
14.4.2 Key Person
14.4.3 Recent Developments
14.4.4 SWOT Analysis
14.4.5 Revenue Analysis

14.5 Roche Holding AG.
14.5.1 Overviews
14.5.2 Key Person
14.5.3 Recent Developments
14.5.4 SWOT Analysis
14.5.5 Revenue Analysis

14.6 Sanofi S.A.
14.6.1 Overviews
14.6.2 Key Person
14.6.3 Recent Developments
14.6.4 SWOT Analysis
14.6.5 Revenue Analysis

14.7 Agilent Technologies
14.7.1 Overviews
14.7.2 Key Person
14.7.3 Recent Developments
14.7.4 SWOT Analysis
14.7.5 Revenue Analysis

14.8 bioMérieux
14.8.1 Overviews
14.8.2 Key Person
14.8.3 Recent Developments
14.8.4 SWOT Analysis
14.8.5 Revenue Analysis